Concepedia

Publication | Open Access

Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma

DOIFull Paper Access

1.9K

Citations

26

References

2013

Year

Robert J. Motzer, Thomas E. Hutson, David Cella, James A. Reeves, Robert D. Hawkins, Jun Guo, Paul Nathan, Michael Staehler, Paul de Souza, Jaime R. Merchan,
New England Journal of Medicine

Abstract

Pazopanib and sunitinib have similar efficacy, but the safety and quality-of-life profiles favor pazopanib. (Funded by GlaxoSmithKline Pharmaceuticals; COMPARZ ClinicalTrials.gov number, NCT00720941.).

References

YearCitations

Page 1